Revolution Medicines Inc (RVMD) Reports Earnings: R&D Investments Surge Amidst Clinical Progress [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
Net Loss : Net loss widened to $161.5 million in Q4 2023 from $56.5 million in Q4 2022. Cash Position : Cash, cash equivalents, and marketable securities stood at $1.85 billion as of December 31, 2023. 2024 Financial Guidance : Projected GAAP net loss between $480 million and $520 million for the full year 2024. Warning! GuruFocus has detected 4 Warning Signs with RVMD. On February 26, 2024, Revolution Medicines Inc ( NASDAQ:RVMD ) released its 8-K filing , detailing its financial results for the fourth quarter and full year of 2023. The clinical-stage oncology company, known for its targeted therapies for RAS-addicted cancers, reported a decrease in revenue and a significant increase in research and development expenses as it advances its RAS(ON) inhibitors through clinical trials. Company Overview Revolution Medicines Inc is at the forefront of precision oncology, developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and surviv
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $43.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Revolution Medicines: An Expensive Shot At A Massive Market Opportunity [Seeking Alpha]Seeking Alpha
- Aptevo Therapeutics, TRACON Pharmaceuticals, BioSig Technologies among healthcare movers [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. (NASDAQ: RVMD) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $48.00 price target on the stock, up previously from $36.00.MarketBeat
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 2/26/24 - Miss
RVMD
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- RVMD's page on the SEC website